Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment
Authors:
- J.-S. F. SandersJSJ.-S. F. Sanders
- M. G. HuitmaMHM. G. Huitma
- C. G. M. KallenbergCKC. G. M. Kallenberg
- C. A. StegemanCSC. A. Stegeman
Open Access
- 6 January 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (6) , 724-729
Abstract
Objective. We performed a retrospective evaluation of whether c-ANCA titres (indirect immunofluorescence) and anti-proteinase 3 (PR3)-ANCA levels (ELISA) at diagnosis and following immunosuppressive treatment are predictive of relapse of ANCA-associated vasculitis. Methods. Patients diagnosed with PR3-ANCA-associated vasculitis between 1991 and 2002, with at least 2 yr of follow-up, and treated with cyclophosphamide and corticosteroids only (1991–1996) or switched to azathioprine after induction of remission with cyclophosphamide and corticosteroids (1997–2002) were included. ANCA were assessed by immunofluorescence and direct PR3-specific ELISA at diagnosis and 3, 6, 12, 18 and 24 months after diagnosis. Actuarial relapse-free survival was analysed with the log rank test. Results. We studied 87 patients positive for PR3-ANCA: 46 were on cyclophosphamide maintenance therapy and 41 switched to azathioprine. Overall actuarial relapse-free survival was 72% at 2 yr and 34% at 5 yr. Relapse-free survival did not differ between patients on cyclophosphamide maintenance and patients switched to azathioprine maintenance (P = 0.34). Patients who became and stayed negative for c-ANCA (immunofluorescence) or PR3-ANCA (ELISA) until 24 months after diagnosis had a lower risk of relapse (P = 0.01 and P = 0.02, respectively). Positive c-ANCA (immunofluorescence) titres at 3 [relative risk (RR) 2.0; 95% confidence interval (CI) 1.2–3.8], 12 (RR 1.9; 95% CI 1.1–3.3), 18 (RR 2.9; 95% CI 1.3–4.6) and 24 months (RR 2.6; 95% CI 1.2–5.0) were significantly associated with relapse within 5 yr after diagnosis. PR3-ANCA levels >10 U/ml at 18 (RR 2.7, 95% CI 1.1–4.3) and 24 months (RR 4.6; 95% CI 1.2–6.3) were predictive of relapse within 5 yr. In the azathioprine group, a positive c-ANCA titre at the time of switching to azathioprine (RR 2.2; 95% CI 1.0–5.4) was associated with relapse. Conclusion. Positive c-ANCA (immunofluorescence) and PR3-ANCA (ELISA) titres during early follow-up identify patients at increased risk of relapse.Keywords
This publication has 16 references indexed in Scilit:
- Positive classic antineutrophil cytoplasmic antibody (C‐ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3–related vasculitisArthritis Care & Research, 2004
- Outcome of ANCA-associated renal vasculitis: a 5-year retrospective studyAmerican Journal of Kidney Diseases, 2003
- Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitisNephrology Dialysis Transplantation, 2002
- Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective studyArthritis & Rheumatism, 2000
- An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patientsArthritis & Rheumatism, 2000
- Trimethoprim–Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's GranulomatosisNew England Journal of Medicine, 1996
- Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders.Annals of the Rheumatic Diseases, 1993
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- Anti-neutrophil Cytoplasmic Antibodies and Disease Activity During Long-Term Follow-up of 70 Patients with Systemic VasculitisNephrology Dialysis Transplantation, 1991
- Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritisKidney International, 1990